数字农科院2.0

Design, synthesis and biological evaluation of the positional isomers of the galactose conjugates able to target hepatocellular carcinoma cells via ASGPR-mediated cellular uptake and cytotoxicity

文献类型： 外文期刊

作者： Ye, Wenchong;Tang, Qun;Zhou, Tiantian;Zhou, Cui;Fan, Chuangchuang;Wang, Xiaoyang;Wang, Chunmei;Zhang, Keyu;Liao, Guochao;Zhou, Wen

作者机构：

关键词： Glycoconjugates;ASGPR;Hepatocellular carcinoma;Galactose;Positional isomer

期刊名称： EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

ISSN： 0223-5234

年卷期： 2024 年 264 卷

页码：

收录情况： SCIE（2024版）

摘要： Galactose as a recognizing motif for asialoglycoprotein receptor (ASGPR) is a widely accepted vector to deliver cytotoxic agents in the therapy of hepatocellular carcinoma (HCC), however, the individual hydroxyl group of galactose (Gal) contributed to recognizing ASGPR is obscure and remains largely unanswered in the design of glycoconjugates. Herein, we designed and synthesized five positional isomers of Gal-anthocyanin Cy5.0 conjugates and three Gal-doxorubicin (Dox) isomers, respectively. The fluorescence intensity of Gal-Cy5.0 conjugates accumulated in cancer cells hinted the optimal modification sites of positions C2 and C6. Comparing to the cytotoxicity of other conjugates, C2-Gal-Dox (11) was the most potent. Moreover, Gal-Dox conjugates significantly the toxicity of Dox. A progressively lower internalization capacity and siRNA technology implied the cellular uptake and cytotoxicity directly related to the ASGPR expression level. Accordingly, position C2 of galactose may be the best substitution site via ASGPR mediation in the design of anti-HCC glycoconjugates.

分类号：

  • 相关文献

[1]Changes in carbohydrates and organic acids in leaves and mesocarp tissues during melon (Cucumis melo L.) fruit development. Fu, Q. S.,Zhang, X. Y.,Zhu, H. Q.,Lv, L. H.,Wang, H. S.. 2012

[2]Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics. Wang, Yingchao,Liu, Hongzhi,Liang, Dong,Huang, Yao,Zeng, Yongyi,Xing, Xiaohua,Xia, Jiangbao,Lin, Minjie,Liao, Naishun,Liu, Xiaolong,Liu, Jingfeng,Wang, Yingchao,Liu, Hongzhi,Liang, Dong,Huang, Yao,Zeng, Yongyi,Xing, Xiaohua,Xia, Jiangbao,Lin, Minjie,Liao, Naishun,Liu, Xiaolong,Liu, Jingfeng,Liu, Hongzhi,Liang, Dong,Huang, Yao,Zeng, Yongyi,Liu, Jingfeng,Han, Xiao.

[3]Reveal The Molecular Signatures Of H.epatocellular Carcinoma With Different S izes By Itraq Based Quantitative Proteomics. Liu, Xiaolong,Wang, Yingchao,Wang, Yingchao,Liu, Xiaolong,Liu, Jingfeng,Liu, Jingfeng,Liu, Jingfeng,Zeng, Yongyi,Zeng, Yongyi,Zeng, Yongyi,Xing, Xiaohua,Xia, Jiangbao,Xia, Jiangbao,Xing, Xiaohua,Liang, Dong,Liang, Dong,Liang, Dong,Huang, Yao,Han, Xiao,Huang, Yao,Huang, Yao,Liu, Hongzhi,Liu, Hongzhi,Liu, Hongzhi,Lin, Minjie,Liao, Naishun,Liao, Naishun,Lin, Minjie. 2017

[4]Potentiation of resveratrol-induced apoptosis by matrine in human hepatoma HepG2 cells. Ou, Xiuyuan,Zhang, Xumeng,He, Qiyang,Ou, Xiuyuan,Zhang, Xumeng,He, Qiyang,Ou, Xiuyuan,Chen, Yan,Chen, Yan,Cheng, Xinxin,Cheng, Xinxin.

[5]Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Wu, Yunzhou,An, Ying,Yan, Shijun,Yin, Jiechao,Li, Deshan,He, Jinjiao,Geng, Jingshu,Ye, Xianlong,Yu, Qingzhong,Zhang, Zhenyu.

[6]Proteome Differences between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by iTRAQ-Based Quantitative Proteomics. Wei, Dahai,Zeng, Yongyi,Xing, Xiaohua,Liu, Hongzhi,Lin, Minjie,Liu, Xiaolong,Liu, Jingfeng,Wei, Dahai,Zeng, Yongyi,Xing, Xiaohua,Liu, Hongzhi,Lin, Minjie,Liu, Xiaolong,Liu, Jingfeng,Zeng, Yongyi,Liu, Jingfeng,Han, Xiao,Liu, Xiaolong,Liu, Jingfeng.

[7]The application of proteomics in different aspects of hepatocellular carcinoma research. Xing, Xiaohua,Liang, Dong,Huang, Yao,Zeng, Yongyi,Liu, Xiaolong,Liu, Jingfeng,Liang, Dong,Xing, Xiaohua,Huang, Yao,Zeng, Yongyi,Liu, Xiaolong,Liu, Jingfeng,Huang, Yao,Zeng, Yongyi,Liu, Jingfeng,Han, Xiao.

[8]Role of MicroRNAs in Hepatocellular Carcinoma. Zhu, Zixiang,Zhang, Xiangle,Zheng, Haixue,Wang, Guoqing. 2014

[9]Impact of Traditional Chinese Medicine on Prognosis of Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study. Huixin Yuan,Qianqian Niu,Xiaofei Shang,Liang Zhang,Li Li,Huasheng Yang,Chunyan Gou,Jingying Li,Hongyan Li,Xiuhui Li. 2023

[10]Nanoparticle-mediated SIRT1 inhibition suppresses M2 macrophage polarization and hepatocarcinogenesis in chronic hepatitis B. Zhang, He,Yuan, Feng,Zhao, Nan,Tang, Wenqiang,Zhao, Pengwei,Liu, Chunfa,Chen, Shan,Hou, Xiaolin,Xia, Changyou,Chu, Jun. 2025

[11]A novel photocleavable amino-modified graphene for covalent purification of N-glycans from hepatocellular carcinoma patients' serum for potential biomarkers discovery. Chao, Xuyuan,Yang, Shengjie,Zhang, Baoying,Zang, Xin,Zhang, Jingyi,Liu, Xizi,Chen, Lu,Qi, Lu,Xue, Xiaofeng,Hu, Han,Wang, Xinghe. 2025

[12]Huqi formula suppresses hepatocellular carcinoma growth by modulating the PI3K/AKT/mTOR pathway and promoting T cell infiltration. Donghao Yin,Xiang Li,Xuemeng Yang,Xiaofei Shang,Zhen Li,Jiahao Geng,Yanyu Xu,Zijing Xu,Zixuan Wang,Zimeng Shang,Zhiyun Yang,Linlan Hu,Quanwei Li,Jiabo Wang,Xinhua Song,Xiuhui Li,Xiaojun Wang. 2025

[13]Schistosoma japonicum sja-let-7 Inhibits the Growth of Hepatocellular Carcinoma Cells via Cross-Species Regulation of Col1α2. Haoran Zhong,Bowen Dong,Danlin Zhu,Zhiqiang Fu,Jinming Liu,Guiquan Guan,Yamei Jin. 2024

作者其他论文 更多>>